butoxamine has been researched along with flavan-3-ol in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kamio, N; Osakabe, N; Suhara, Y; Suzuki, T; Watanabe, Y | 1 |
| Ebe, R; Fukase, S; Horikoshi, Y; Inagawa, K; Osakabe, N; Saito, A; Shibata, M | 1 |
2 other study(ies) available for butoxamine and flavan-3-ol
| Article | Year |
|---|---|
A single oral dose of flavan-3-ols enhances energy expenditure by sympathetic nerve stimulation in mice.
Topics: Adrenergic beta-2 Receptor Antagonists; Adrenergic beta-3 Receptor Antagonists; Animals; Butoxamine; Energy Metabolism; Flavonoids; Male; Mice, Inbred ICR; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Propanolamines; Sympathetic Nervous System; Uncoupling Protein 1 | 2016 |
Onset of a hypotensive effect following ingestion of flavan 3-ols involved in the activation of adrenergic receptors.
Topics: Adrenergic Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Butoxamine; Cacao; Carbazoles; Carvedilol; Catechin; Epinephrine; Flavonoids; Gene Expression Regulation; Heart Rate; Male; Nitric Oxide Synthase Type III; Phosphorylation; Prazosin; Propanolamines; Rats; Rats, Wistar; Receptors, Adrenergic; Yohimbine | 2016 |